98%
921
2 minutes
20
Brain metastasis is very common in lung cancer and it's a fatal disease with extremely poor prognosis. Until now, there has been a lack of accurate and efficient prognostic models for patients with lung cancer brain metastases (LCBM), and the factors influencing the effectiveness of the surgery on primary lesion for these patients remain unclear. We used 7 machine learning algorithms to create prognostic models to predict the overall survival (OS) of LCBM based on the data from the Surveillance Epidemiology and End Results. Then, a series of validation methods, including area under the curve values, receiver operating characteristic curve analysis, calibration curves, decision curve analysis and external data validation were used to confirm the high discrimination, accuracy, and clinical applicability of the XGBoost models. Propensity score matching adjusted analysis was conducted for further stratified analysis to find factors influencing the benefit of surgery on primary lesion for LCBM. Models using XGBoost algorithm performed best. Surgery on primary lesion was a favorable independent prognostic factor for LCBM. Age > 70 years old, blacks, grade IV, stage T4, N3, other distant organ metastases, squamous cell carcinoma, large cell carcinoma and no radiation were all unfavorable factors of primary lung tumor surgery for the prognosis of LCBM. Our study is the first one to create highly accurate AI models to predict the OS of LCBM. Our in-depth stratified analysis found some influence factors of surgery on primary lesion for the prognosis of LCBM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626286 | PMC |
http://dx.doi.org/10.62347/PRFQ9244 | DOI Listing |
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
J Cancer Surviv
September 2025
Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Purpose: Despite its importance, little is known about the patterns and predictors of Survivorship Clinic attendance in head and neck cancer (HNC). We sought to determine the cumulative incidence of Survivorship Clinic attendance stratified by demographic, clinical, and socioeconomic factors, and to identify factors independently associated with attendance.
Methods: Our analysis population consisted of 2,252 patients diagnosed with primary HNC and seen at our institution's HNC Survivorship Clinic after completing treatment from 2016-2021.
Ann Surg Oncol
September 2025
Department of HPB Surgery and Liver Transplant, Royal Free Hospital NHS Foundation Trust, London, UK.
Ann Surg Oncol
September 2025
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, USA.
Brain Imaging Behav
September 2025
Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, South 4th Ring West Road 119, Fengtai District, Beijing, 100070, China.
To explore the effect of brain cognitive compensation on the pathogenesis of postoperative delirium (POD) in the frontal glioma patients. Eighty-four adult patients with unilateral frontal glioma who underwent elective craniotomy and 37 healthy controls were recruited. Primary outcomes were POD during postoperative 1-7 days, as assessed by Confusion Assessment Method.
View Article and Find Full Text PDF